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Background. The live attenuated inﬂuenza vaccine (LAIV) is the preferred vaccine for children, but the mech-
anisms behind protective immune responses are unclear, and the duration of immunity remains to be elucidated.
This study reports on the longevity of B-cell and T-cell responses elicited by the LAIV.
Methods. Thirty-eight children (3–17 years old) were administered seasonal LAIV. Blood samples were collected be-
fore vaccinationwith sequential sampling up to 1 year after vaccination. Humoral responses were evaluated by a hemagglu-
tination inhibition assay, and memory B-cell responses were evaluated by an enzyme-linked immunosorbent spot assay
(ELISpot). T-cell responses were evaluated by interferon γ (IFN-γ) ELISpot analysis, and intracellular cytokine staining of
CD4+ T cells for detection of IFN-γ, interleukin 2, and tumor necrosis factor α was performed using ﬂow cytometry.
Results. LAIV induced signiﬁcant increases in B-cell and T-cell responses, which were sustained at least 1 year after
vaccination. Strain variations were observed, in which the B strain elicited stronger responses. IFN-γ–expressing T cell
counts increased signiﬁcantly, and remained higher than prevaccination levels 1 year later. Expression of T-helper type 1
intracellular cytokines (interleukin 2, IFN-γ, and tumor necrosis factor α) increased after 1 dose and were boosted after the
second dose. Hemagglutination inhibition titers were sustained for 1 year. Vaccine-induced memory B cell counts were
signiﬁcantly increased, and the response persisted for one year.
Conclusions. LAIV elicited B-cell and T-cell responses that persisted for at least 1 year in children. This is a novel
ﬁnding that will aid future vaccine policy.
Keywords. inﬂuenza; LAIV; humoral; T-cellular; longevity; pediatric; IFN-γ.
Annually, inﬂuenza virus infection has a large socioeco-
nomic burden on society, with 500 000 fatal cases glob-
ally [1–3]. The World Health Organization estimates
that 20% of children are infected with inﬂuenza virus
each year, and they are the main source of spread of
the virus and have a high burden of the disease [4]. Vac-
cination is the cornerstone of prophylaxis and is recom-
mended for high-risk patients. The trivalent inactivated
inﬂuenza vaccine (TIV) is safe and provides protection
but may not be the optimal vaccine for young children,
owing to their lack of previous infection. Since 2003,
the cold-adapted live attenuated inﬂuenza vaccine
(LAIV), administered as a nasal spray, has been ap-
proved in the United States for individuals aged 2–49
years. The vaccine was licensed in Europe in 2012
(for individuals aged 2–17 years) and was implemented
in the British childhood vaccination campaign, begin-
ning in 2013 [5]. In June 2014, the Advisory Committee
on Immunization Practices preferentially recommended
LAIV in healthy children 2–8 years old when it is imme-
diately available [6].
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Despite many years on the market, there are no established
correlates of protection for LAIV. Efﬁcacy studies and observa-
tional data suggest that the LAIV provides higher levels of pro-
tection than TIV in children [7–11]. The hemagglutination
inhibition (HI) titer is widely used as a surrogate correlate of pro-
tection after TIV receipt; however, the cutoff titer of 1:40 is based
on adult trials. There is debate on both the protective HI level in
children and the fact that an HI titer underestimates the protec-
tion obtained by LAIV [12–14]. Cellular immunity may be a bet-
ter measure of protective immunity after LAIV in children [15].
CD4+ T cells have the ability to act as effector cells and to direct
and generate speciﬁc memory CD4+ and CD8+ T-cell subsets
with diverse functions [16–18]. Animal and human studies
have demonstrated protective cellular immunity after LAIV
[10, 19–21]. Therefore, the duration and quality of the immune
response in humans after LAIV needs to be studied.
We conducted a pediatric clinical trial to elucidate the immu-
nological mechanisms induced by LAIV, with emphasis on the
long-term, strain-speciﬁc cellular immune responses. Our study
is unique, as we obtained sequential blood samples from young
children up to 1 year after vaccination, allowing us to compare
and analyze serum and cellular responses in the same child. Our
results indicate that LAIV induces long-term humoral and
cellular immune responses in children and that priming is
important in determining the magnitude of the response.
MATERIALS AND METHODS
Patients and Study Design
Thirty-eight healthy children, consisting of 20 boys and 18 girls
aged 3–17 years old, were recruited at Haukeland University
Hospital (HUH) in Norway. From October 2012 to January
2013, children were immunized with the trivalent seasonal LAIV
(Fluenz, Astra Zeneca, Birmingham, United Kingdom). Fluenz
contained 107.0 ﬂuorescent focus units of attenuated reassortant
of A/California/7/2009(H1N1)pdm09-like, A/Victoria/361/
2011(H3N2)-like, and B/Wisconsin/1/2010 strains. The vaccine
was administered intranasally as 0.1 mL per nostril. Children 3–
9 years old received 2 doses at a 4-week interval, and children
≥10 years old received a single dose of vaccine as recommended
by the manufacturer. The study was approved by the Regional
Ethical Committee of Western Norway and the Norwegian
Medicines Agency and was monitored by HUH (clinical trials
registration, NCT01866540; EUDRACT registration 2012-
002848-24).
Upon enrollment, parents and children aged ≥12 years pro-
vided voluntary, written informed consent. We collected data
on baseline demographic characteristics, medical and inﬂuenza
vaccination history, and risk factors for inﬂuenza virus infec-
tion. All procedures were conducted at the pediatric trial unit
at HUH. Children with mild-to-moderate asthma (clinically
stable with daily use of inhalators) or who had received prior
inﬂuenza vaccination were included. Exclusion criteria are listed
in Figure 1. A self-reported questionnaire of local and systemic
side effects was completed after each vaccination.
Samples
Blood samples (volume, 8 mL) were collected after vaccination
(Figure 1). Fresh peripheral blood mononuclear cells (PBMCs)
were isolated using Cell Preparation Tubes (BD, New Jersey)
[22]. Plasma samples were aliquoted and stored at −80°C before
use in the HI assay.
HI Assay
Plasma samples from each individual were tested in duplicate by
means of an HI assay, using 8 hemagglutination units of the
Figure 1. Study design. Healthy children scheduled for elective tonsillectomy were recruited from the Ear, Nose, and Throat Department, Haukeland
University Hospital (HUH), Bergen, Norway. Thirty-eight children received live attenuated inﬂuenza vaccine (LAIV), and 29 children (all <10 years old) re-
ceived a second dose. Blood samples were collected before vaccination and at 4 time points after vaccination. The number of subjects providing samples at
each time point is shown. Not all children provided blood samples at all visits, owing to difﬁculty in obtaining blood samples with a sufﬁcient volume (ie, 8
mL). Exclusion criteria were as follows: serious, chronic medical conditions; serious asthma; recent inﬂuenza; fever; pregnancy; use of acetyl salicylic acid
(ASA) or immunosuppressive therapy; allergy to the vaccine components or earlier complications to vaccination; or under governmental custody.
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homologous H1N1 and H3N2 vaccine strains and 0.7% turkey
red blood cells [23]. HI titers were deﬁned as the reciprocal of
the dilution causing 50% HI. Negative titers were assigned a
value of 5 for calculation purposes.
Interferon γ (IFN-γ) Enzyme-Linked Immunosorbent Spot
(ELISpot) Assay
IFN-γ–precoated 96-well plates were used according to
the manufacturer’s instructions (Mabtech, Sweden). PBMCs
(400 000 cells/well) in Roswell Park Memorial Institute medium
plus 10% fetal calf serum were added to wells, along with nega-
tive control (medium alone) or inﬂuenza virus antigens (5 µg/mL
of split virus vaccine of each strain; H1N1, H3N2, B). Plates were
incubated overnight (37°C, 5%CO2) and developed the following
day. The plates were read using the Immunoscan reader and as-
sociated software (CTL-Europe). The negative control was sub-
tracted from the inﬂuenza virus–speciﬁc response.
Intracellular Cytokine Staining (ICS) of CD4+ T Cells
Expression of the inﬂuenza virus–speciﬁc T-helper type 1 (Th1)
cytokines (IFN-γ, interleukin 2 [IL-2], and tumor necrosis factor
α {TNF-α}) were measured using ICS of CD4+ T-cells. PBMCs
were stimulated overnight with a mixture of the 3 split-virus an-
tigens in the vaccine (H1N1, H3N2 and B; 2.5 µg/mL of each
protein) in the presence of brefeldin A, monensin, and anti-
CD28 and anti-CD49 antibodies (BD Bioscience, San Jose).
After overnight stimulation, cells were stained and analyzed
on a BD LSR II ﬂow cytometer for the expression of IFN-γ,
IL-2, and TNF-α, as described earlier [24]. The antibodies
used are provided in Supplementary Table 1, and the gating
strategy is speciﬁed in Supplementary Figure 2.
Memory B-Cell Response, Determined by ELISpot
The antigen-speciﬁc immunoglobulin G (IgG), immunoglobulin
A (IgA), and immunoglobulin M (IgM) memory B-cell responses
after vaccination were quantiﬁed by ELISpot, as described by Pa-
thirana et al [25] and Crotty et al [26]. Inﬂuenza virus–speciﬁc im-
munoglobulin-secreting cells per million PBMCs are presented as
percentages of the total IgG, IgA, and IgM responses, respectively.
Statistics
Statistical analyses were performed in SPSS, version 17, and
GraphPad Prism, version 5 for Mac (GraphPad Software, San
Diego, California). For all statistical tests, a P value of < .05 was
considered signiﬁcant. ICS results were compared using t test.
For the remaining results, analysis of variance (by the Kruskal–
Wallis test) with multiple comparisons testing was used.
RESULTS
Study Subjects
Thirty-eight healthy children, including 6 with asthma, received
the LAIV (median age, 4 years). Ten children did not receive a
second dose owing to an age of ≥10 years (n = 8), concurrent
illness at the time of vaccination (n = 1), and withdrawal from
the study (n = 1). Samples were collected before and after vacci-
nation with sampling points as indicated in Figure 1.
Safety and Side Effects
The vaccine was easy to administer and well tolerated. Adverse
events were solicited by questionnaires during the initial 7 days
after vaccination, and 46% of children reported no side effects
after the ﬁrst dose. Reported side effects were mild and mostly
local. Seven children (18%) reported runny/congested nose, and
4 (11%) reported systemic side effects (Supplementary Figure 1).
Six children had mild or moderate asthma (clinically stable with
daily use of local steroids and β2 agonists), of whom 5 reported no
side effects after vaccination and 1 reported transient local side
effects. Parents of the asthmatic children did not report asthma
exacerbation during the trial. In general, reactions often started
2 days after vaccination and mainly lasted 1–3 days (data not
shown). One severe adverse event required consultation but not
treatment; this occurred in a healthy 17-year-old girl with non-
typical inﬂuenza-like illness symptoms of arthralgia. After the
second dose, 26 children (90%) reported no side effects, and 3
(10%) reported mostly local side effects (Supplementary
Figure 1).
HI Antibody Response Against Inﬂuenza Virus A Strains
Persists for 1 Year
Figure 2A and 2B show the HI response to the H1N1 and H3N2
strains before and after LAIV receipt. An HI titer of ≥40 was
considered a protective response.
Before vaccination, the majority of children (25 [66%]) had
protective antibody titers toward H1N1 (geometric mean titer
[GMT], 71; 95% conﬁdence interval {CI}, 40–125). Thirteen
children did not have protective HI titers, of whom 9 had no
detectable antibody (HI titer, < 10) to the H1N1 virus. An in-
crease in HI titer occurred after the ﬁrst dose (day 28; GMT, 95;
95% CI, 55–164) and after the second dose (day 56; GMT, 111;
95% CI, 64–194), when 27 subjects (84%) had a protective an-
tibody titer (9% seroconverted). Eighteen subjects had HI titers
of ≥40 to the H1N1 virus at 180 days, and 6 subjects had no
detectable antibodies. At day 360, 11 of 14 children (79%)
had a protective HI level (≥40), of whom 3 seroconverted, but
2 of these children had high prevaccination levels. Two children
had no detectable antibodies. Four children without prevaccina-
tion antibodies remained seronegative throughout the study.
For the H3N2 strain, 14 (37%) of the 18 children (47%) with an
HI titer of < 40 were seronegative (HI titer, 5; GMT, 37; 95% CI,
20–68; Figure 2). After the ﬁrst dose, there was a signiﬁcant in-
crease in HI titers (P < .0001) in all children except 2, reaching
protective HI levels (GMT, 286; 95% CI, 203–401). The increase
observed after the second dose was signiﬁcant, compared with the
titer on day 0 (P < .001), as well as the titer on day 180 (P < .01),
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and 47% of the children seroconverted. One 4-year-old child had
an HI titer of 40 after 2 doses but had no detectable titers at other
time points. The antibody titers remained elevated 180 days after
vaccination, with 96% of subjects (n =23) having protective HI ti-
ters (GMT, 229; 95% CI, 147–357). At day 360, 12 subjects (86%)
had sustained a protective HI antibody response (GMT, 169; 95%
CI, 69–410), while the titer in only 2 children remained <40. Of
the 14 children evaluated at day 360, 8 (57%) seroconverted.
There was no signiﬁcant difference in the durability of the HI
response for either strain in children receiving 1 or 2 doses of
vaccine (Supplementary Figure 3).
Long-term Increased IFN-γ Response
We measured the IFN-γ response by using an ELIspot, and we
observed interstrain variations. The highest numbers of speciﬁc
IFN-γ–secreting cells after vaccination were towards the B
strain, followed by the H3N2 strain, and the lowest numbers was
to the H1N1 strain. Before vaccination, the majority of children
(77%) had levels of IFN-γ–secreting T-cells of ≥100 spot-form-
ing cells (SFCs)/106 PBMCs that were speciﬁc to H1N1, which
is a suggested level of protection against inﬂuenza (Figure 3A)
[15]. There was a signiﬁcant increase in IFN-γ–secreting cells 28
days after the ﬁrst dose (P < .05) and a further increase after the
Figure 2. Hemagglutination inhibition (HI) antibody titers after vaccination. Children were intranasally vaccinated with 1 (for those aged ≥10 years) or 2
(for those aged <10 years; doses were administered at a 28-day interval) doses of live attenuated inﬂuenza vaccine. HI antibody titers to H1N1 (A) and H3N2
(B) were measured at the following time points: day 0 (before vaccination), day 28 (after the ﬁrst dose), day 56 (after the second dose), and days 180 and 360
after vaccination. Each symbol represents the HI response of 1 child, with bold horizontal lines and whiskers denoting geometric mean titers and 95%
conﬁdence intervals, respectively. The dotted line represents an HI titer of 40, considered the protective level [27]. The statistical signiﬁcance of differences
from prevaccination levels was determined by analysis of variance, using the nonparametric Kruskal–Wallis test. **P < .01, ***P < .001, and ****P < .0001.
Figure 3. Long-term interferon γ (IFN-γ) immune response in blood after live attenuated inﬂuenza vaccination (LAIV). The long-term immune response
was evaluated by measuring the number of IFN-γ–producing T cells, measured as spot-forming cells (SFCs)/106 peripheral blood mononuclear cells (PBMCs)
after LAIV, using the IFN-γ enzyme-linked immunosorbent spot assay. Children were intranasally vaccinated with 1 (for those aged <10 years) or 2 (for those
aged ≥10 years; doses were administered at a 28-day interval) doses of LAIV. Blood samples were collected at 0, 28, 56, 180, and 360 days after vac-
cination. Each symbol represents the inﬂuenza virus–speciﬁc SFCs/106 PBMCs for each child for each inﬂuenza strain in the vaccine (A, B, C), with bold
horizontal lines and whiskers denoting mean values and standard errors of the mean, respectively. The dotted line represents 100 SFCs/106 PBMCs, con-
sidered the protective level [15]. The statistical signiﬁcance of differences from prevaccination levels was determined by analysis of variance, using the
nonparametric Kruskal–Wallis test. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
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second dose (P < .001). The levels declined toward day 180, de-
creasing below the proposed protective level at day 360 after
vaccination, but the mean value remained higher than prevac-
cination levels, although the difference was not signiﬁcant. Six
of the 7 children with ≥100 SFCs before vaccination had re-
ceived the Pandemrix vaccine.
For the H3N2 strain (Figure 3B), 20 subjects (65%) had <100
SFCs/106 PBMCs before vaccination, and the numbers of H3N2-
speciﬁc IFN-γ–secreting cells increased signiﬁcantly after the ﬁrst
(P < .05) and second (P = .01) doses. Levels declined toward day
180 and increased slightly again by day 360, remaining above the
suggested protective level of 100 SFCs/106 PBMCs, although the
difference from prevaccination levels was not signiﬁcant. Nine of
the 11 children with ≥100 SFCs/106 PBMCs before vaccination
had received the Pandemrix vaccine. There was no signiﬁcant dif-
ference in IFN-γ response in children receiving 1 or 2 doses (Sup-
plementary Figure 4)
The response was highest toward the B strain, with 25 sub-
jects (80%) exhibiting <100 SFCs/106 PBMCs before vacc-
ination, but it increased signiﬁcantly after the ﬁrst dose
(P < .0001), with a subsequent boost after the second dose
(P < .0001). By days 180 and 360, the levels declined, but the
mean levels remained above the protective level and were signif-
icantly higher than at day 0 (P < .001 and P < .05, respectively).
The IFN-γ response at each time point after vaccination was
plotted against the HI response at day 0 (the prevaccination ef-
fect) and day 28 (the postvaccination effect) after immuniza-
tion. There was a signiﬁcant correlation between the fold
increase in HI titer for H1N1 and the fold increase in IFN-γ se-
cretion (Spearman r = 0.438; P = .036), but the correlation was
not observed for H3N2 (data not shown).
Further analysis of the 5 children who remained seronegative
(HI titer, 5) to the H1N1 strain after vaccination (2 doses) found
a signiﬁcant increase in inﬂuenza virus–speciﬁc IFN-γ respons-
es after vaccination (P = .029).
Increased Multifunctional CD4+ T-Cell Response After LAIV
Receipt
Figure 4A shows that the frequency of Th1 CD4+ T cells that
express a single cytokine (IFN-γ, IL-2, or TNF-α) increased
after the ﬁrst dose and was signiﬁcantly higher after the second
immunization, compared with prevaccination levels. Similarly,
the percentage of multifunctional CD4+ T cells expressing
either 2 (IFN-γ and IL-2, or IL-2 and TNF-α) or 3 (IFN-γ,
IL-2, and TNF-α) cytokines increased after the ﬁrst dose and
signiﬁcantly increased after the second dose, compared with
prevaccination levels (Figure 4B).
Increased Long-term Memory B-Cell Response After LAIV
Receipt
We evaluated the long-term inﬂuenza virus–speciﬁc memory B-
cell response (IgG+, IgA+, and IgM+) after LAIV receipt (Figure 5).
Overall, the highest frequencies were measured toward the B
strain, and the lowest were observed toward the H1N1 strain.
The levels of H1N1-speciﬁc IgG+ memory B cells were high
before vaccination and remained elevated at all sampling points
after vaccination. The IgM+ memory B-cell frequencies to
H1N1 increased signiﬁcantly at all time points after vaccination
(P < .01), whereas the IgA+ memory B-cell response was only
signiﬁcantly higher on day 360 (P < .01).
For the H3N2 strain, IgG+ memory B cells increased after the
ﬁrst dose of vaccine, with a signiﬁcant boost (P < .001) after the
second dose. The frequencies of H3N2-speciﬁc IgG+ memory B
Figure 4. The CD4+ T cell cytokine (T-helper type 1 [Th1]) response be-
fore and after vaccination. Peripheral blood mononuclear cells obtained
before vaccination (day 0) and 28 and 56 days after vaccination were sim-
ulated overnight with split-virus antigen from a mixture of the 3 virus
strains in the vaccine (H1N1, H3N2, and B). The percentage of CD4+ T
cells secreting either single (A) or multiple (B) Th1 cytokines was measured
by multiparametric ﬂow cytometry. *P < .05, by the Student t test, compared
with the CD4+ T-cell response before vaccination (day 0). Abbreviations:
IFN-γ, interferon γ; IL-2, interleukin 2; TNF-α, tumor necrosis factor α.
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cells were maintained at day 180 (P < .01) and decreased at day
360, although they remained higher than at day 0. We did not
detect increased levels of IgA+ memory B cells to H3N2 at any
time point after vaccination; in contrast, IgM+ memory B cells
increased signiﬁcantly at all time points (P < .01).
For inﬂuenza B, the frequencies of all immunoglobulin
classes of memory B cells increased signiﬁcantly after 1 dose
of vaccine, with P values of <.05 for IgG and IgA and <.001
for IgM, for which the highest numbers were observed. After
the second immunization, both the IgG+ and IgM+ memory B
Figure 5. Long-term memory B-cell (MBC) responses after live attenuated inﬂuenza vaccination (LAIV). The frequencies of inﬂuenza virus–speciﬁc im-
munoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM)–expressing MBCs before and after LAIV receipt. MBCs were stimulated to
proliferate and differentiate into antibody-secreting cells by mitogens in vitro, and levels were subsequently measured by an enzyme-linked immunosorbent
spot assay. The y-axis shows the percentage of inﬂuenza virus–speciﬁc MBCs. IgG+, IgM+, and IgA+ MBCs were measured against the 3 inﬂuenza virus
strains in the vaccine. Data are represented as the percentage of antigen-speciﬁc IgG+, IgA+, and IgM+ MBCs among all IgG+, IgA+, and IgM+ MBCs,
respectively. Each symbol represents 1 child. IgA+ and IgM+ MBC frequencies for day 180 were not determined because of laboratory constraints. The
lines represent mean values ± standard errors of the mean. The statistical signiﬁcance of differences from prevaccination levels was determined by analysis
of variance, using the nonparametric Kruskal–Wallis test. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
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cells increased signiﬁcantly (P < .01). At day 360, the frequencies
remained higher than those observed before vaccination for all 3
immunoglobulins.
DISCUSSION
Clinical pediatric trials with LAIV generally focus on short-
term responses after 1 or 2 doses or on efﬁcacy studies per-
formed during inﬂuenza seasons [9, 28, 29]. Less is known
about the long-term immunological responses, but there are
studies reporting the durability of serum and local antibodies
and the efﬁcacy of LAIV [30, 31]. The aim of this study was
to evaluate the longevity of the humoral and cellular immune
responses elicited by LAIV in young children, with a focus on
the effect of priming. To our knowledge, our study is unique in
reporting the long-term immune responses to LAIV in children,
including those with asthma. We found that the vaccine was safe
and easy to administer, with mild side effects after the ﬁrst dose
and even fewer side effects after the second dose (Supplementa-
ry Figure 1).
This study was conducted during a postpandemic period,
when the H1N1 strain dominated. In general, the highest im-
mune response was against the B strain, followed by the
H3N2 strain, with the lowest response against the H1N1 strain.
The total levels of serum IgG, IgA, and IgM were stable
throughout the study period [32]. The serological response to
LAIV was evaluated by an HI assay, with differences observed
in the response to the H1N1 and H3N2 strains. Before vaccina-
tion, the majority of the children had protective antibody titers
(HI titer, ≥40) against the H1N1 strain, which did not increase
after vaccination but remained elevated 1 year after vaccination.
This may be because H1N1 was a dominant circulating inﬂuen-
za A strain in 2009 and 2010. Hence, most of the children were
primed, either by natural infection or pandemic vaccination
[33]. As LAIV must replicate to elicit an immune response,
the presence of preexisting antibodies or cross-reactive T cells
in primed children could inhibit virus infection and replication,
resulting in lower HI responses. In contrast, the H3N2 strain
circulated to a much lesser degree in Norway; hence, most
children were unprimed against this strain [33]. The B strain
had limited circulation in the prior seasons, except during
2010–2011; it is therefore possible that most children were
naive to this strain, consistent with the observation that
LAIVs elicit stronger immune responses in unprimed children
[34]. Apart from priming, differences in infectivity among the
vaccine strains could also impact the subsequent immune
response. We saw no difference in durability of the immune
response after 1 or 2 doses of vaccine (Supplementary Figures 3
and 4).
Induction of long-term immunological memory is the ulti-
mate goal of vaccination. In this study, levels of inﬂuenza
virus–speciﬁc memory B cells increased after vaccination and
were maintained for 1 year. Memory B cells can rapidly differ-
entiate into antibody-secreting plasmablasts upon antigen reen-
counter. They may possess broad cross-reactivity and the ability
to go through secondary afﬁnity maturation to altered antigenic
epitopes [35, 36]. The IgG+ and IgA+ memory B-cell responses
in our study were strain dependent. When we divided the chil-
dren according to a protective HI titer of 40, we observed that,
in inﬂuenza virus–primed children, the levels of memory B cells
were not boosted upon vaccination (data not shown). The lack
of a boosting response after vaccination in B cells in primed in-
dividuals has previously been described in adults [37, 38]. In
contrast to the IgG+ and IgA+ memory B-cell responses, the
IgM+ memory B-cell response increased signiﬁcantly against
all 3 inﬂuenza virus strains. Recent research suggests that iso-
type-switched, afﬁnity-matured memory B cells dominate the
antibody-secreting cell response on antigen recall, while the ma-
jority of IgM+ memory B cells contain less somatic hypermuta-
tions and dominate the formation of new germinal centers [38,
39]. Furthermore, it has been suggested that IgM+ memory B
cells live longer than their isotype-switched counterparts [39].
Thus, the inﬂuenza virus–speciﬁc IgM+ memory B cells may
contain a population with the potential to respond to novel an-
tigenic variants (eg, drifted inﬂuenza viruses). The observed
strain variations may indicate a biological threshold for memory
B-cell responses in children with preexisting memory B cells
due to previous inﬂuenza virus exposure.
LAIV mimics natural infection and activates the innate im-
mune system, as well as both humoral and T-cell responses,
which play a key role in cross-reactive anti–inﬂuenza virus re-
sponses [10, 21]. T cells depend on major histocompatibility
complex presentation of viral antigens and, hence, cannot pre-
vent infection per se. Human studies have shown naturally ac-
quired CD4+ and CD8+ T cells to be important in limiting
disease and may provide heterosubtypic immunity, which
may inﬂuence the inﬂuenza A (H1N1 and H3N2) response
[40, 41]. T cells respond to conserved epitopes, which is why
the response to inﬂuenza A viruses is interlinked. Importan-
tly, cross-reactive T cells elicited by LAIV have the potential
to protect against drifted strains and shifted pandemic strains.
This has been demonstrated in animal models [42, 43]. LAIV-
induced cross-reactive antibodies have been found in humans,
but it has yet to be determined whether LAIV induces cross-
protective T cells in humans.
Using a direct ELISpot assay, we determined the IFN-γ T-cell
response following LAIV immunization. This ELISpot assay is
more sensitive than serum antibody responses in determining
the inﬂuenza virus–speciﬁc memory immune response with
an arbitrary number of 100 SFC/106 PBMCs suggested as a pro-
tective level against clinical inﬂuenza after LAIV in a trial of
>2000 children [15]. Interestingly, 5 subjects in our study
who, on the basis of HI assays, did not seroconvert to H1N1
had a signiﬁcant increase in their IFN-γ response after 2 vaccine
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doses, which may provide clinical protection. In fact, HI titers
are known to underestimate the protective effect achieved by the
LAIV in children, and clinical efﬁcacy studies on LAIV have
shown high levels of protection against laboratory-conﬁrmed
inﬂuenza despite low HI titers [7, 44, 45]. Studies in adults
have found that LAIV elicits higher CD4+ T-cell responses
than TIV to the variant region of hemagglutinin, suggesting
that antigenically distinct mutants that escape antibody re-
sponses may still be recognized by T cells [21].
Recent studies suggest that CD4+ T cells that simultaneously
secrete IFN-γ, IL-2, or TNF-α (multifunctional T cells) are
functionally superior than single cytokine producers at induc-
ing anti–inﬂuenza virus immunity [46]. In this study, we have
shown that LAIV induces a signiﬁcant increase in both sin-
gle-cytokine and multifunctional Th1 responses in children.
The magnitude of the Th1 cytokine responses induced after
LAIV receipt was lower than observed in adult subjects after in-
tramuscular vaccination with candidate pandemic vaccines [25,
47].Differences in the route of administration (intramuscular or
intranasal) and formulation with the adjuvant in immunologi-
cally naive subjects could partly explain the superiority of the
parenteral vaccine at inducing a Th1 response in peripheral
blood. However, in children, LAIV has been shown to be a bet-
ter inducer of T-cell responses than TIV [10, 48, 49]. This may
explain, at least in part, the higher efﬁcacy of LAIV, compared
with TIV, in children during head-to-head clinical trials [29].
Nonetheless, vaccine-induced long-lived memory CD4+ T
cells may provide broader protection and should be a goal of
novel vaccines [18]. With respect to cytotoxic T cells, we did
not detect an increase in antigen-speciﬁc CD8+ T-cell responses
at any time point after LAIV receipt. This is most likely due to
the use of split virus proteins for in vitro PBMC stimulation, re-
sulting in inefﬁcient antigen cross-presentation to stimulate a
CD8+ T-cell response.
Here, we have demonstrated that LAIV elicits elevated and
sustained humoral and T-cell responses in young children at
least 1 year after vaccination and that there is great interstrain
variation in responses. This was recently addressed by the Ad-
visory Committee on Immunization Practices, which noted that
the LAIV gave less protection than TIV against the H1N1 strain
alone [6]. This study provides support to public health ofﬁcials
in determining the beneﬁt of their childhood vaccine programs
when considering safety and obtaining long-lasting immune re-
sponses toward inﬂuenza virus.
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